New lung drug ENV-101 put through safety checks in healthy volunteers

NCT ID NCT07454291

Recruiting now Knowledge-focused Sponsor: Endeavor Biomedicines, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage study tests how a new drug called ENV-101 (taladegib) interacts with two standard medicines for idiopathic pulmonary fibrosis (IPF): nintedanib and pirfenidone. About 57 healthy adults will take ENV-101 alone and with these drugs to measure how the body absorbs and processes them. The goal is to gather safety and drug-level data, not to treat IPF.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: taladegib (ENV-101)
What this could lead to: If successful, this study could help doctors understand how to safely combine ENV-101 with existing IPF treatments.
What could go wrong: This is an early-phase study in healthy people, not patients. It only measures drug levels and interactions, not whether ENV-101 works for IPF.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

idiopathic pulmonary fibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IDIOPATHIC PULMONARY FIBROSIS

Contacts and locations

Locations

Research Site
RECRUITING

Brisbane, Queensland, 4006, Australia
Research Site
RECRUITING

Melbourne, Victoria, 3004, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.